Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – December 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024 | Press Releases

Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentrationMarlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ:...

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024 | Press Releases

Journal is the official publication of the International Union of Immunological SocietiesMarlborough, Massachusetts–(Newsfile Corp. – December 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing...

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024 | Press Releases

Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts–(Newsfile Corp. – December 10, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that...